Once-weekly subcutaneous amycretin produced substantial, dose-dependent weight loss in adults with overweight or obesity. These results were presented at the European Association for the Study of Diabetes 2025 Annual Meeting. A single-center, double-blind study assessed the safety, pharmacokinetics, and efficacy of single- and multiple-ascending doses of amycretin in adults with BMI 27–39.9 kg/m². Participants received amycretin or placebo across five study parts, with dose escalation ranging from 0.3 mg to 60 mg once weekly.

The most common treatment-emergent adverse events were gastrointestinal, including nausea, vomiting, and diarrhea, and were largely mild or moderate. Pharmacokinetic analyses showed dose-proportional increases in drug exposure (AUC and Cmax).

Across all dosing regimens, amycretin produced significant reductions in body weight compared with placebo. At the highest dose (60 mg), participants lost an average of 24.3% of body weight over 36 weeks versus 1.1% with placebo. Lower doses also yielded meaningful reductions in weight, demonstrating a clear dose-response relationship.

Overall, once-weekly amycretin demonstrated a safety profile consistent with GLP-1 and amylin agonists while providing substantial, dose-dependent weight loss, supporting further clinical development in obesity management.